Deutsche Bank Aktiengesellschaft Begins Coverage on Harmony Biosciences (NASDAQ:HRMY)

Analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences (NASDAQ:HRMY) in a report released on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $55.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 45.35% from the stock’s current price.

A number of other brokerages also recently commented on HRMY. Needham & Company LLC restated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research note on Monday, January 27th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald boosted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Trading Up 0.3 %

Shares of NASDAQ:HRMY opened at $37.84 on Tuesday. The firm has a fifty day moving average of $35.89 and a two-hundred day moving average of $35.56. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61. The firm has a market capitalization of $2.16 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 1,123 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC grew its position in Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares in the last quarter. CWM LLC increased its stake in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after acquiring an additional 775 shares during the period. KBC Group NV raised its holdings in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after acquiring an additional 819 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Harmony Biosciences in the 3rd quarter worth approximately $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.